Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s Favorable Impact on Cardiac Structure Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT); […]

SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker […]